Biosimilar Patent Thicketing Has Cost US $7.6bn

 
• By Akriti Seth
Syringe
US patients, taxpayers and the healthcare system are bearing the costs of patent schemes: AAM • Source: Shutterstock

More from Biosimilars

More from Products